Physician profile
Timothy R Couch
NPI 1285295113
$20,268.93
in general payments reported to CMS, 2019-2025
14 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $135 · 2022: $108 · 2023: $669 · 2024: $1,979 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $5,414 · Travel and Lodging: $761 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,839.00 |
| Food and Beverage | $5,413.87 |
| Travel and Lodging | $761.08 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $16,008.88 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $887.15 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $826.32 | 2021-2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $752.58 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $616.90 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $258.52 | 2024 | Ingrezza |
| Abbvie INC. | $225.11 | 2023-2025 | |
| Alkermes, INC. | $159.17 | 2021-2025 | Lybalvi |
| Vanda Pharmaceuticals INC. | $144.82 | 2025 | Fanapt |
| E.R. Squibb & Sons, L.L.C. | $126.23 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $124.74 | 2025 | Jornay Pm |
| Neurelis, INC. | $94.50 | 2025 | Valtoco |
| Lundbeck LLC | $24.01 | 2025 | Abilify Asimtufii |
| Indivior INC. | $20.00 | 2023 | Perseris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Couch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.